Mary Teresa Shoemaker
Independent DirectorMs. Mary Teresa Shoemaker, also known as Terri, has been an Independent Director of Traws Pharma, Inc. (formerly known as Onconova Therapeutics, Inc.) since April 2020. Ms. Shoemaker was the President and CEO of the United States Operations at Medexus Pharmaceuticals Inc. from December 17, 2018 to June 10, 2020. Ms. Shoemaker served as Chief Executive Officer and President of Medac Pharma, Inc. since October 16, 2013. Prior to joining Medac Pharma, Ms. Shoemaker served as a Vice President of Sales at InterMune Inc. from November 2009 to July 2010. Before joining InterMune, Inc. in 2009, Ms. Shoemaker co-founded BioPharm Strategic Solutions, providing pre-commercial, commercial, operational and strategic guidance for start-up pharmaceutical and biotechnology organizations. Previously, Ms. Shoemaker served as Principal and Co-Founder of BioPharm Strategic Solutions from 2010 to 2012. In 2002, Ms. Shoemaker joined Pharmion Corporation, serving as National Sales Director and then Senior Director of U.S. Commercial Operations, building and leading its specialty oncology organization. Most recently at Pharmion, she was responsible for creating the commercial organization and the successful launch of Vidaza. In 2008, when Celgene Corporation acquired Pharmion Corporation, Ms. Shoemaker served as its Executive Director of Strategic Commercial Operations, working as part of the executive transition team charged with building the new and fully aligned commercial organization. Ms. Shoemaker held senior commercial leadership positions at Du Pont Pharmaceuticals and Bristol-Myers Squibb. She was a Director of Medac Pharma, Inc. since June 2012. Ms. Shoemaker holds B.S. degrees in Communication Science and Psychology from Missouri State University and a M.S. degree in Communication Science and Disorders from University of Central Missouri.
Positions
- Company NameTraws Pharma, Inc.Stock CodeTRAWPositionIndependent DirectorColleagues
